Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areata

New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). 

According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningful scalp hair regrowth among study participants treated for up to 68 weeks, as measured by the Severity of Alopecia Tool (SALT) scores. Study authors pooled data from open-label extension (OLE) trials, assessing deuruxolitinib 8 mg tablets administered twice daily. At 24 weeks, 32.6% of patients achieved SALT scores ≤20, reflecting significant hair regrowth. By Week 68, 48.8% of patients met SALT ≤20 under Last Observation Carried Forward (LOCF) analysis, while 76.6% achieved this score under As Observed (AO) analysis. Furthermore, nearly all patients (99.6%) maintained their response, sustaining SALT ≤50 scores.

“This research provides insight into the durability of response experienced with LEQSELVI 8 mg twice daily, adding to a growing body of evidence highlighting the benefits of this treatment for those living with severe alopecia areata,” Investigator Brett King, MD, PhD, said in a press release.

Additional findings suggested both patients and clinicians prioritized fast-acting and efficacious treatments for AA, with LEQSELVI consistently chosen as the preferred option when compared to other JAK inhibitors. 

“The data support a growing body of clinical evidence, which show LEQSELVI is an effective treatment option for those living with severe alopecia areata," Sun Pharma’s Senior Vice President, Marek Honczarenko, MD, PhD, said in a news release.

Source: Sun Pharma press release. October 25, 2024.